Loading company
Verastem, Inc.
VSTM · Nasdaq · ·
Next earnings: November 3, 2026
$7.91+1.7%Sep 29 close
- 1M
- +9.6%
- 6M
- +63.1%
- 1Y
- -10.4%
- 5Y
- -79.5%
VSTM · Nasdaq · ·
Next earnings: November 3, 2026
$7.91+1.7%Sep 29 close
Verastem, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $40.1M | $2.1M | +1,775.43% |
| Profit | -$34.7M | -$25.9M | -33.70% |
| Profit per share | -$0.35 | -$0.62 | +43.55% |
| Free Cash Flow | -$25.1M | -$9.9M | -152.68% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and increased refills,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Verastem, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Verastem, Inc. has no earnings call transcript available.